Shots:

• Baxter signs an agreement with Sanofi to acquire Seprafilm Adhesion Barrier and related assets for $350M with expected closure of transaction in Q1’20
• The focus of the acquisition to expand Baxter’s advanced surgery portfolio that accompany the portfolio of hemostat and sealant across the hospital- including in the operating room
• Seprafilm Adhesion Barrier is targeted for undergoing abdominal or pelvic laparotomy for reducing the incidence- extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera and is marketed in the US- Japan- China- South Korea and France

Click here to­ read full press release/ article | Ref: Baxter | Image: Twitter